Codon-specific <i>KRAS</i> mutations predict survival in advanced pancreatic cancer.

ABSTRACT:

Background

How distinct KRAS alterations in pancreatic adenocarcinoma (PDAC) influence tumor initiation and outcomes remains unclear. Moreover, KRAS is now partly targetable with novel specific inhibitors targeting KRAS _G12 (G12C or G12D), but specific outcomes of these subgroups of patients is poorly described. In this study, we compared clinical/genomic characteristics and outcomes of PDAC depending on codon-specific KRAS mutant (G12 versus others), as well as gene expression profiles and in vitro drug sensibility using organoids.

Patients and methods

All metastatic patients with PDAC and available molecular profile from 2015 to 2022 were eligible, and patients with KRAS mutation were included. Transcriptomic data from 6

SUBMITTER: Boileve A 

PROVIDER: S-EPMC12836696 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature